1. Home
  2. CSWC vs TSHA Comparison

CSWC vs TSHA Comparison

Compare CSWC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSWC
  • TSHA
  • Stock Information
  • Founded
  • CSWC 1961
  • TSHA 2019
  • Country
  • CSWC United States
  • TSHA United States
  • Employees
  • CSWC N/A
  • TSHA N/A
  • Industry
  • CSWC Textiles
  • TSHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CSWC Consumer Discretionary
  • TSHA Health Care
  • Exchange
  • CSWC Nasdaq
  • TSHA Nasdaq
  • Market Cap
  • CSWC 1.3B
  • TSHA 1.3B
  • IPO Year
  • CSWC N/A
  • TSHA 2020
  • Fundamental
  • Price
  • CSWC $20.65
  • TSHA $5.07
  • Analyst Decision
  • CSWC Buy
  • TSHA Strong Buy
  • Analyst Count
  • CSWC 5
  • TSHA 8
  • Target Price
  • CSWC $23.70
  • TSHA $9.38
  • AVG Volume (30 Days)
  • CSWC 646.3K
  • TSHA 11.4M
  • Earning Date
  • CSWC 10-27-2025
  • TSHA 11-12-2025
  • Dividend Yield
  • CSWC 12.35%
  • TSHA N/A
  • EPS Growth
  • CSWC N/A
  • TSHA N/A
  • EPS
  • CSWC 1.64
  • TSHA N/A
  • Revenue
  • CSWC $209,032,000.00
  • TSHA $8,098,000.00
  • Revenue This Year
  • CSWC $14.60
  • TSHA N/A
  • Revenue Next Year
  • CSWC $10.75
  • TSHA N/A
  • P/E Ratio
  • CSWC $12.59
  • TSHA N/A
  • Revenue Growth
  • CSWC 10.52
  • TSHA N/A
  • 52 Week Low
  • CSWC $17.46
  • TSHA $1.05
  • 52 Week High
  • CSWC $25.90
  • TSHA $5.40
  • Technical
  • Relative Strength Index (RSI)
  • CSWC 30.86
  • TSHA 71.89
  • Support Level
  • CSWC $20.70
  • TSHA $4.32
  • Resistance Level
  • CSWC $22.18
  • TSHA $5.40
  • Average True Range (ATR)
  • CSWC 0.46
  • TSHA 0.32
  • MACD
  • CSWC -0.16
  • TSHA 0.17
  • Stochastic Oscillator
  • CSWC 11.27
  • TSHA 75.42

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: